Plus Therapeutics to Present at the LD Micro Main Event (XII)
November 25 2019 - 7:00AM
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today
announced that it will be participating at the upcoming 12th annual
LD Micro Main Event.
Dr. Marc Hedrick, President and Chief Executive Officer of Plus
Therapeutics, will be presenting on Wednesday, December 11, 2019,
at 12:40 p.m. PST (3:40 p.m. EST) and meeting with investors. A
live webcast of the presentation will be available at
wsw.com/webcast/ldmicro17/pstv.
The LD Micro Main Event will take place on December 10-12 in Los
Angeles at the Luxe Sunset Bel Air Hotel. The Main Event will
feature 275 companies and be attended by over 1,400
individuals.
Plus Therapeutics’ profile may be viewed at
ldmicro.com/profile/PSTV.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an
independent resource in the microcap space. What started out as a
newsletter highlighting unique companies has transformed into
several influential events annually (Invitational, Summit, and Main
Event).
In 2015, LDM launched the first pure microcap index (the LDMi)
to exclusively provide intraday information on the entire sector.
LD will continue to provide valuable tools for the benefit of
everyone in the small and microcap universe.
About Plus Therapeutics, Inc.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical
company focused on the discovery, development, and manufacturing
scale up of complex and innovative treatments for patients battling
cancer and other life-threatening diseases.
Our proprietary nanotechnology platform is currently centered
around the enhanced delivery of a variety of drugs using novel
liposomal encapsulation technology. Liposomal encapsulation has
been extensively explored and undergone significant technical and
commercial advances since it was first developed. Our platform is
designed to facilitate new delivery approaches and/or formulations
of safe and effective, injectable drugs, potentially enhancing the
safety, efficacy and convenience for patients and healthcare
providers.
Our lead product candidate, DocePLUS, is a protein-stabilized
PEGylated liposomal formulation of docetaxel, for which the process
of preparation is patented. The active pharmaceutical ingredient,
docetaxel, was approved by the U.S. FDA in 1999 and commonly used
for treating cancers of the breast, head, neck, stomach, prostate,
and lung. More information may be obtained at
plustherapeutics.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains certain statements that may be
deemed “forward-looking statements” within the meaning of U.S.
securities laws. All statements, other than statements of
historical fact, that address activities, events or developments
that we intend, expect, project, believe or anticipate and similar
expressions or future conditional verbs such as will, should,
would, could or may occur in the future are forward-looking
statements. Such statements are based upon certain assumptions and
assessments made by our management in light of their experience and
their perception of historical trends, current conditions, expected
future developments and other factors they believe to be
appropriate. These statements include, without limitation,
statements about: the Company’s potential to facilitate new
delivery approaches and/or formulations of safe and effective,
injectable drugs, potentially enhancing the safety, efficacy and
convenience for patients and healthcare providers; the Company’s
potential to develop a market leading position; and the potential
for, and timing of, the Company’s submission of a Phase 2 clinical
trial protocol in Small Cell Lung Cancer patients with
platinum-sensitive disease who progressed at least 60 days after
initiation of first-line chemotherapy. The forward-looking
statements included in this press release are subject to a number
of additional material risks and uncertainties, including but not
limited to: the risk that the U.S. FDA does not accept the
Company’s submission of a Phase 2 clinical trial protocol in Small
Cell Lung Cancer patients with platinum-sensitive disease who
progressed at least 60 days after initiation of first-line
chemotherapy; the risk that the Company is not able to successfully
develop product candidates that can leverage the U.S. FDA’s
accelerated regulatory pathways; and the risks described under the
heading “Risk Factors” in the Company’s Securities and Exchange
Commission filings, including in the Company’s annual and quarterly
reports. There may be events in the future that the Company is
unable to predict, or over which it has no control, and its
business, financial condition, results of operations and prospects
may change in the future. The Company assumes no responsibility to
update or revise any forward-looking statements to reflect events,
trends or circumstances after the date they are made unless the
Company has an obligation under U.S. federal securities laws to do
so.
Plus Therapeutics, Inc. Russ Havranek VP
– Marketing, Portfolio Management, Investor Relations Phone:
+1.619.333.4150 Email: ir@plustherapeutics.com
Website: plustherapeutics.com
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Sep 2023 to Sep 2024